NTHI$10.22
Chart
Performance
Key Stats
AI NTHI Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldNeOnc Technologies Holdings, Inc. (NTHI) shows potential in its specialized oncology treatments, but faces significant financial and operational challenges. Its current valuation and market position warrant a 'Hold' rating, with a need for close monitoring of clinical trial progress and financial stability.
Thematic
Thematic tailwinds for NeOnc Technologies are primarily centered around advancements in targeted cancer therapies, particularly for brain tumors. While the field is high-growth, the company's specific stage and competitive landscape present a mixed outlook.
Fundamental
NeOnc Technologies Holdings demonstrates very low revenue and significant net losses, indicative of its clinical-stage status. The company's cash position and debt levels require careful consideration for its ongoing operational capacity and future funding needs.
Technical
The stock price has seen a significant short-term surge, evidenced by strong recent performance (1M, 5D). However, the long-term trend (1Y) is sharply negative, and key technical indicators suggest potential overbought conditions and near-term volatility.
| Factor | Score |
|---|---|
| Oncology Drug Development | 80 |
| Biotechnology Innovation | 70 |
| Healthcare Spending Trends | 75 |
| Regulatory Landscape (FDA, EMA) | 60 |
| Market Adoption of Novel Therapies | 65 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 30 |
| Balance Sheet Health | 15 |
| Cash Flow | 20 |
| Debt Load | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 10 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Moving Averages | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Improving Valuation Metrics
The Price-to-Sales (PS) ratio has decreased from 4851.8 in 2022 to 1169.1 in 2024, suggesting the stock is becoming more reasonably valued relative to its revenue.
Positive Short-Term Performance
The stock has shown strong performance over the last month (+38.59%) and 5 days (+5.37%), indicating recent positive momentum.
Bearish Points (8)
Significant Net Losses
The company has consistently reported substantial net losses, with a net income of -$11,898,464 in 2024 and -$14,921,065 in 2023, indicating a lack of profitability.
Extremely High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio is very high at 1169.1 for 2024 and 1377.1 for 2023, suggesting the company is significantly overvalued relative to its sales.
Profile
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.